Shoreline Biosciences Wins a Comprehensive Summary Judgement Victory on All Claims Brought by Fate Therapeutics and Whitehead Institute on iPSC Generation and Use
Shoreline Biosciences to Participate at the 2023 Wedbush Pacgrow Healthcare Conference
A highly efficient transgene knock-in technology in clinically relevant cell types
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a
BioWorld Insider Podcast: One-on-one with Medical Innovators
Another record year for biopharma financings bodes well for 2022 Listen to the podcast! In another record year for biopharma fundraisings, more money than ever
BioWorld Insider Podcast: One-on-one with Medical Innovators
Another record year for biopharma financings bodes well for 2022 https://www.bioworld.com/ext/resources/Podcast-files/bioworld_ep12_061221_edit2.mp3?1639088948 In another record year for biopharma fundraisings, more money than ever pulsed through the
Harnessing the body’s natural killers to target cancer
Natural killer cells, the body’s first line of defence against emerging cancers, could be engineered into powerful, off-the-shelf cancer therapies. Natural killer (NK) cells are
Intelligent Cells: Shoreline Builds Immunotherapy Platform, Pipeline with $140M Financing
CEO Kleanthis Xanthopoulos touts the San Diego biotech’s engineering prowess in developing iPSC-derived NK cells and macrophages against cancerBy Alex Philippidis November 8, 2021 Shoreline
Shoreline Biosciences Wins a Comprehensive Summary Judgement Victory on All Claims Brought by Fate Therapeutics and Whitehead Institute on iPSC Generation and Use
San Diego, September 7, 2023 – Shoreline Biosciences, Inc., a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs)
Shoreline Biosciences to Participate at the 2023 Wedbush Pacgrow Healthcare Conference
SAN DIEGO, Aug. 3, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural
Shoreline Biosciences Announces Appointment of Steve Potter as Vice President of People and Culture
San Diego, Calif., June 16, 2023 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem
Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells
SAN DIEGO, March 16, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Shoreline Biosciences to Present Data at AACR 2023 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells
SAN DIEGO, March 16, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its
Shoreline Biosciences Announces Appointment of Mauro P. Avanzi, M.D., Ph.D., As Chief Medical Officer
SAN DIEGO, Feb. 21, 2023 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its